Principle of Assay
13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) ELISA Kit (A326823) employs the competitive enzyme immunoassay technique for the quantitative measurement of 13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) in serum, plasma, cell culture supernatant, cell or tissue lysate, and other liquid samples. The 96-well microtiter plate has been pre-coated with 13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) antigen. During the incubation, 13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) present in the samples or standards competes with the fixed amount of immobilized 13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) for binding sites on the Biotinylated Anti-13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) Antibody. The more 13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) present in a sample or standard, the less Biotinylated Anti-13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) Antibody that binds to the plate. Following incubation, unbound Biotinylated Anti-13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) Antibody is removed by washing, and an HRP-Streptavidin conjugate is added to the wells and the microtiter plate is incubated. Following incubation and washing, TMB substrate solution is then used to visualize the HRP enzymatic reaction by catalysis to produce a blue-coloured product that changes to yellow after addition of acidic stop solution. The density of yellow is inversely proportional to the amount of 13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) present in each sample or standard. The concentration of 13,14 Dihydro-15-keto Prostaglandin F2 alpha (PGFM) can then be calculated by reading the O.D. absorbance at 450nm in a microplate reader and referring to the standard curve.